<DOC>
	<DOCNO>NCT01984255</DOCNO>
	<brief_summary>This Open label , two-arm , randomize , two agent , single center trial .</brief_summary>
	<brief_title>A Two-arm , Single Center Phase 1b Trial Bavituximab Plus Ipilimumab Advanced Melanoma Patients</brief_title>
	<detailed_description>This Open label , two-arm , randomize , two agent , single center trial . Study Product ( ) , Dose , Route , Regimen : Bavituximab 3mg/kg IVqwk ( IV every week ) x 14 plus ipilimumab 3mg/kg IVq3wk ( IV every 3 week ) x 4 ipilimumab 3mg/kg IVq3wk x 4 Administration Schedule : Patients randomize one follow arm : Arm A—Bavituximab 3mg/kg IV 90 minute weekly x 2 follow Bavituximab 3mg/kg IV 90 minute weekly x 12 plus ipilimumab 3mg/kg IV 90 minute every 3 week x 4 . Total number treat patient 16 . Arm B—Arm B—Ipilimumab 3mg/kg IV 90 minute day 1 follow three week later ipilimumab every 3 week x 3 . Total number treat patient 8 . Randomization : There 2:1 randomization patient 3 week lead-in treatment bavituximab follow combination therapy ipilimumab + bavituximab versus ipilimumab alone . The assigned treatment give subject register successfully . Endpoints : Toxicities assess via NCI 's CTCAE ( Common Terminology Criteria Adverse Events ) v4.1 toxicity criterion . Dose limit toxicity ( DLTs ) define drug-related grade 3-5 adverse event experience within first 12 week study treatment . The maximal tolerate dose ( MTD ) exceed 30 % patient study experience DLTs . DCR measure irRC ( Immune-related Complete Response ) week 15 , 21 , 27 use publish algorithm . Disease control rate ( DCR ) include complete response ( CR ) , Partial response ( PR ) stable disease ( SD ) . Months survival ( MOS ) measure date entry protocol . Tumor MDSC ( Myeloid-Derived Suppressor Cells ) , TAM Treg content measure IHC ( ImmunoHistoChemistry ) . Circulating MDSC , TAM Treg content measure flow cytometry . Peripheral blood cytokine measure EIA ( EIA test series blood test diagnose HIV infection ) .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Histologic diagnosis unresectable metastatic melanoma . For unknown primary disease , diagnosis metastatic disease cytology FNA ( Fine Needle Aspiration ) acceptable . 2 . Any number prior systemic therapeutic regimen include chemotherapy , pathway inhibitor , biochemotherapy , investigational agent , immunotherapy ipilimumab bavituximab . 3 . Subjects must measurable disease define irRC . All site must evaluate within 4 week prior begin therapy . 4 . Age ≥ 18 year . 5 . Performance status ECOG ( Eastern Cooperative Oncology Group ) 02 . 6 . Adequate organ marrow function define : leukocyte ≥ 2,000/mcL ( Microliter ) absolute neutrophil count ≥ 1,500/mcL platelet ≥ 100,000/mcl total bilirubin &lt; 3X ( time ) institutional upper limit normal AST ( Aspartate Aminotransferase ) ( SGOT ) /ALT ( Alanine Aminotransferase ) ( SPGT ) ≤ 2.5 X institutional upper limit normal creatinine &lt; 3X institutional upper limit normal hemoglobin &gt; 8g/dL 7 . Ability understand willingness sign write informed consent . 8 . Subjects must willing undergo tumor biopsy pretreatment week 3 15 . 9 . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration study participation , 90 day follow completion therapy . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . A female childbearing potential woman ( regardless sexual orientation , undergone tubal ligation , remain celibate choice ) meet follow criterion : undergone hysterectomy bilateral oophorectomy ; naturally postmenopausal least 12 consecutive month ( i.e. , menses time precede 12 consecutive month ) . 1 . No concomitant therapy following : IL2 ( Interleukin 2 ) , interferon , nonstudy immunotherapy regimen ; cytotoxic chemotherapy ; immunosuppressive agent ; investigational therapy ; chronic use systemic corticosteroid ; therapy must discontinue &gt; 4weeks . 2 . No infection HIV active infection hepatitis B active chronic infection hepatitis C. Due mechanism action ipilimumab , activity side effect immune compromise patient unknown . 3 . Subjects active CNS ( Central nervous system ) disease exclude . Patient brain metastases previously treat surgery stereotactic radiosurgery confirm SD &gt; 8 week allow . 4 . Subjects exclude history malignancy patient diseasefree less 2 year , exception adequately treat cured basal squamous cell skin cancer , superficial bladder cancer carcinoma situ cervix . 5 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 6 . Subjects must pregnant nursing . 7 . Any concurrent medical condition require use systemic steroid permit ( use inhale topic steroid permit ) . 8 . Subjects exclude receive nononcology vaccine therapy use prevention infectious diseases 4 week ( 28 day ) prior dose ipilimumab . 9 . Subjects exclude history prior treatment ipilimumab , CD137 agonist , CTLA4 inhibitor ( Cytotoxic TLymphocyte Antigen 4 ) agonist bavituximab . 10 . Patients exclude history autoimmune disease except control stable autoimmune thyroiditis . The excluded autoimmune disease include acute disseminated encephalomyelitis , Addison 's disease , alopecia universalis , ankylose spondylitis , antiphospholipid antibody syndrome , aplastic anemia , asthma , autoimmune hemolytic anemia , autoimmune hepatitis , autoimmune hypoparathyroidism , autoimmune hypophysitis , autoimmune myocarditis , autoimmune oophoritis , autoimmune orchitis , autoimmune thrombocytopenic purpura , Behcet 's disease , bullous pemphigoid , celiac disease , chronic fatigue syndrome , chronic inflammatory demyelinate polyneuropathy , ChurgStrauss syndrome , Crohn 's disease , dermatomyositis , dysautonomia , eczema , epidermolysis bullossa acquisita , gestational pemphigoid , giant cell arteritis , Goodpasture 's syndrome , Graves ' disease , GuillainBarre syndrome , Hashimoto 's diseaseexcept note , IgA nephropathy ( Berger 's disease ) , inflammatory bowel disease , interstitial cystitis , Kawasaki 's disease , LambertEaton myasthenia syndrome , lupus erythematosis , chronic Lyme disease , Meniere 's syndrome , Mooren 's ulcer , Morphea , multiple sclerosis , myasthenia gravis , neuromyotonia , opsoclonus myoclonus syndrome , optic neuritis , Ord 's thyroiditis , pemphigus , pernicious anemia , polyarteritis nodosa , polyarthritis , polyglandular autoimmune syndrome , primary biliary cirrhosis , psoriasis , Reiter 's syndrome , rheumatoid arthritis , sarcoidosis , Sjogren 's syndrome , StiffPerson syndrome , Takayasu 's arteritis , ulcerative colitis , Vogt KovanagiHarada disease , vulvodynia , Wegener 's granulomatosis . 11 . Subjects exclude history thromboembolic event , clinically significant bleeding—gross hematuria , hemoptysis , gastrointestinal bleeding , history bleed diathesis hypercoagulable state , ongoing therapy anticoagulant nonsteroidal antiinflammatory drug , prior exposure chimeric antibody .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>